Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer ; volume:41 ; number:6 ; day:21 ; month:9 ; year:2024 ; pages:937-945 ; date:12.2024
Clinical & experimental metastasis ; 41, Heft 6 (21.9.2024), 937-945, 12.2024
- Urheber
-
Welsch, Eva
Bonstingl, Lilli
Holzer, Barbara
Schuster, Eva
Weiß, Esther
Zaharie, Alexandru-Teodor
Krainer, Michael
Fischer, Michael B.
El-Heliebi, Amin
Zeillinger, Robert
Obermayr, Eva
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10585-024-10313-2
- URN
-
urn:nbn:de:101:1-2503012123572.417424676262
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Welsch, Eva
- Bonstingl, Lilli
- Holzer, Barbara
- Schuster, Eva
- Weiß, Esther
- Zaharie, Alexandru-Teodor
- Krainer, Michael
- Fischer, Michael B.
- El-Heliebi, Amin
- Zeillinger, Robert
- Obermayr, Eva
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Transport costs, intermediate goods, and localized growth
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hypofractionated radiotherapy for localized prostate cancer
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
Treatment of metastatic lesions localized in the acetabulum
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Transport costs, intermediate goods, and localized growth
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hypofractionated radiotherapy for localized prostate cancer
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
Treatment of metastatic lesions localized in the acetabulum
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Transport costs, intermediate goods, and localized growth
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Hypofractionated radiotherapy for localized prostate cancer
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer